The pharmaceutical industry spends US$1 billion to develop a product for conditions with much less impact – if there is a market. But for HIV/AIDS the people of the principal “market” have incomes of under $1 a day. There are only two ways they can be cared for – by government institutions and academia taking the place of the industry, or at least paying for it to do what is necessary. Neither is happening on anything like a sufficient scale to tackle the extraordinary human and the scientific challenge of HIV.
HIV is a unique virus in human experience, devastating our immune system - which might otherwise present a natural defence; and transmitted in 80% of cases by a great human pleasure and biological necessity – sex. (Two other transmission routes are related: at childbirth, and through breast-feeding; the third is by needle-sharing in intravenous drug use.)
The immune system it attacks is highly evolved, complex and only partially understood. And the psychology and sociology of sexual behaviour might be said to be the same, varying enormously from culture to culture and almost always under a screen of discretion: we do not easily talk openly about our sex lives, or easily change our behaviour. Drug use is also hidden behind a veil.
The great challenge for Europe, with its long history of close involvement with the developing countries where the burden of HIV/AIDS is highest, in Africa, Latin America and increasingly in Asia, is – at sufficient scale - to investigate the quickest and most effective routes to ease the burden of sufferers and their families; to address with much greater vigour and intelligence the fundamental, practical and simply managerial problems facing the creation of effective vaccines, microbicidal barriers, and new treatments, aiming to attract the brightest scientists and managers of a generation; and to complement and combine this work with related efforts elsewhere.
Jens Degett | alfa
Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine
Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
13.11.2018 | Life Sciences
13.11.2018 | Life Sciences
13.11.2018 | Awards Funding